MetLife Investment Management LLC Has $92.17 Million Stock Holdings in Johnson & Johnson (NYSE:JNJ)

MetLife Investment Management LLC grew its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 1.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 637,349 shares of the company's stock after acquiring an additional 11,299 shares during the quarter. Johnson & Johnson accounts for 0.5% of MetLife Investment Management LLC's holdings, making the stock its 25th biggest position. MetLife Investment Management LLC's holdings in Johnson & Johnson were worth $92,173,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Oregon Pacific Wealth Management LLC acquired a new position in shares of Johnson & Johnson during the 4th quarter worth about $949,000. Horan Securities Inc. boosted its position in Johnson & Johnson by 1.3% during the fourth quarter. Horan Securities Inc. now owns 7,178 shares of the company's stock valued at $1,038,000 after purchasing an additional 90 shares during the last quarter. Strategic Financial Concepts LLC grew its stake in Johnson & Johnson by 57.9% in the fourth quarter. Strategic Financial Concepts LLC now owns 3,467 shares of the company's stock valued at $501,000 after purchasing an additional 1,271 shares in the last quarter. Lord Abbett & CO. LLC acquired a new position in shares of Johnson & Johnson during the 3rd quarter worth approximately $69,859,000. Finally, KPP Advisory Services LLC raised its stake in shares of Johnson & Johnson by 4.7% during the 4th quarter. KPP Advisory Services LLC now owns 11,492 shares of the company's stock worth $1,662,000 after purchasing an additional 515 shares in the last quarter. 69.55% of the stock is owned by institutional investors.

Insider Activity

In other news, EVP Timothy Schmid sold 403 shares of the business's stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total transaction of $62,928.45. Following the transaction, the executive vice president now owns 15,098 shares of the company's stock, valued at approximately $2,357,552.70. The trade was a 2.60 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, VP Robert J. Decker sold 6,999 shares of the stock in a transaction dated Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the completion of the sale, the vice president now directly owns 21,001 shares in the company, valued at $3,483,645.88. This trade represents a 25.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.16% of the company's stock.

Johnson & Johnson Stock Up 2.3 %

Shares of Johnson & Johnson stock opened at $157.42 on Friday. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86. The company has a 50-day moving average of $159.49 and a 200 day moving average of $155.03. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $169.99. The firm has a market cap of $379.37 billion, a price-to-earnings ratio of 23.67, a PEG ratio of 2.56 and a beta of 0.49.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, topping the consensus estimate of $2.59 by $0.18. The company had revenue of $21.89 billion during the quarter, compared to the consensus estimate of $21.65 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. As a group, sell-side analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th will be given a dividend of $1.30 per share. This is a positive change from Johnson & Johnson's previous quarterly dividend of $1.24. The ex-dividend date of this dividend is Tuesday, May 27th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.30%. Johnson & Johnson's dividend payout ratio is currently 74.59%.

Analysts Set New Price Targets

Several research firms have issued reports on JNJ. StockNews.com raised shares of Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research report on Saturday, January 25th. Bank of America reduced their price target on Johnson & Johnson from $171.00 to $159.00 and set a "neutral" rating for the company in a report on Thursday, April 10th. Argus upgraded Johnson & Johnson to a "strong-buy" rating in a research note on Friday, January 24th. Wells Fargo & Company reduced their target price on Johnson & Johnson from $166.00 to $152.00 and set an "equal weight" rating for the company in a research note on Thursday, January 23rd. Finally, Raymond James dropped their price target on Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating on the stock in a research note on Monday, April 14th. Nine equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $171.82.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.